J Virol

• 

  Publication Venue For

  • Impact of Th1 CD4 TFH skewing on Antibody Responses to an HIV-1 Vaccine in Rhesus Macaques. 2019
  • Hepatitis C Virus Infection Is Inhibited by a Noncanonical Antiviral Signaling Pathway Targeted by NS3-NS4A..  93. 2019
  • Boosting with AIDSVAX B/E enhances Env constant region 1 and 2 antibody-dependent cellular cytotoxicity breadth and potency. 2019
  • A CRISPR Screen Identifies the Cell Polarity Determinant Crumbs 3 as an Adeno-associated Virus Restriction Factor in Hepatocytes..  93. 2019
  • Correction for Kibler et al., "Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC"..  93. 2019
  • Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial..  93. 2019
  • Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes..  93. 2019
  • Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge..  93. 2019
  • Vaccine-Mediated Inhibition of the Transporter Associated with Antigen Processing Is Insufficient To Induce Major Histocompatibility Complex E-Restricted CD8+ T Cells in Nonhuman Primates..  93. 2019
  • Simian-Human Immunodeficiency Virus SHIV.CH505-Infected Infant and Adult Rhesus Macaques Exhibit Similar Env-Specific Antibody Kinetics, despite Distinct T-Follicular Helper and Germinal Center B Cell Landscapes..  93. 2019
  • The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity..  93. 2019
  • Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen..  93. 2019
  • Modulation of Sialic Acid Dependence Influences the Central Nervous System Transduction Profile of Adeno-associated Viruses..  93. 2019
  • Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models..  93. 2019
  • Adaptation of an R5 Simian-Human Immunodeficiency Virus Encoding an HIV Clade A Envelope with or without Ablation of Adaptive Host Immunity: Differential Selection of Viral Mutants..  93. 2019
  • Rare Detection of Antiviral Functions of Polyclonal IgA Isolated from Plasma and Breast Milk Compartments in Women Chronically Infected with HIV-1..  93. 2019
  • Coadministration of CH31 Broadly Neutralizing Antibody Does Not Affect Development of Vaccine-Induced Anti-HIV-1 Envelope Antibody Responses in Infant Rhesus Macaques..  93. 2019
  • Intrahost Dynamics of Human Cytomegalovirus Variants Acquired by Seronegative Glycoprotein B Vaccinees..  93. 2019
  • Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes..  93. 2019
  • Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC..  93. 2019
  • Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques..  92. 2018
  • Antisense-Derived HIV-1 Cryptic Epitopes Are Not Major Drivers of Viral Evolution during the Acute Phase of Infection..  92. 2018
  • Engineered Oncolytic Poliovirus PVSRIPO Subverts MDA5-Dependent Innate Immune Responses in Cancer Cells..  92. 2018
  • The Influenza B Virus Hemagglutinin Head Domain Is Less Tolerant to Transposon Mutagenesis than That of the Influenza A Virus..  92. 2018
  • Control of Heterologous Simian Immunodeficiency Virus SIVsmE660 Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques..  92. 2018
  • Reply to Gantt et al., "Higher Expectations for a Vaccine To Prevent Congenital Cytomegalovirus Infection"..  92. 2018
  • Mapping and Engineering Functional Domains of the Assembly-Activating Protein of Adeno-associated Viruses..  92. 2018
  • Novel Strategy To Adapt Simian-Human Immunodeficiency Virus E1 Carrying env from an RV144 Volunteer to Rhesus Macaques: Coreceptor Switch and Final Recovery of a Pathogenic Virus with Exclusive R5 Tropism..  92. 2018
  • Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex Vivo..  92. 2018
  • Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape..  92. 2018
  • Intranasal Live Influenza Vaccine Priming Elicits Localized B Cell Responses in Mediastinal Lymph Nodes..  92. 2018
  • HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees..  92. 2018
  • Immunogenicity in Rabbits of HIV-1 SOSIP Trimers from Clades A, B, and C, Given Individually, Sequentially, or in Combination..  92. 2018
  • Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates..  92. 2018
  • Advancing Our Understanding of Protective Maternal Immunity as a Guide for Development of Vaccines To Reduce Congenital Cytomegalovirus Infections..  92. 2018
  • Dengue Virus Selectively Annexes Endoplasmic Reticulum-Associated Translation Machinery as a Strategy for Co-opting Host Cell Protein Synthesis..  92. 2018
  • HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis..  92. 2018
  • A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques..  92. 2018
  • Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells..  92. 2018
  • Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge..  92. 2018
  • Polyploidy and Mitotic Cell Death Are Two Distinct HIV-1 Vpr-Driven Outcomes in Renal Tubule Epithelial Cells..  92. 2018
  • c-Myc Represses Transcription of Epstein-Barr Virus Latent Membrane Protein 1 Early after Primary B Cell Infection..  92. 2018
  • Correction for Hraber et al., "Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments"..  92. 2018
  • HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine..  92. 2018
  • HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine..  91. 2017
  • Pathogenic Correlates of Simian Immunodeficiency Virus-Associated B Cell Dysfunction..  91. 2017
  • HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques..  91. 2017
  • Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques..  91. 2017
  • Increased, Durable B-Cell and ADCC Responses Associated with T-Helper Cell Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site..  91. 2017
  • Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1..  91. 2017
  • Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments..  91. 2017
  • Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers..  91. 2017
  • Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity..  91. 2017
  • Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers..  91. 2017
  • HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates..  91. 2017
  • Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk..  91. 2017
  • Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses..  91. 2017
  • Viral Epitranscriptomics..  91. 2017
  • Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses..  91. 2017
  • RPLP1 and RPLP2 Are Essential Flavivirus Host Factors That Promote Early Viral Protein Accumulation..  91. 2017
  • Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies..  91. 2017
  • Deep Sequencing of Influenza A Virus from a Human Challenge Study Reveals a Selective Bottleneck and Only Limited Intrahost Genetic Diversification..  90:11247-11258. 2016
  • Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001..  90:10362-10378. 2016
  • Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice..  90:10209-10219. 2016
  • Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization..  90:8644-8660. 2016
  • Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques..  90:8842-8854. 2016
  • Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design..  90:5899-5914. 2016
  • Characterization of the Adeno-Associated Virus 1 and 6 Sialic Acid Binding Site..  90:5219-5230. 2016
  • Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates..  90:5315-5328. 2016
  • Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds..  90:5031-5046. 2016
  • Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk..  90:4951-4965. 2016
  • Derivation and Characterization of a CD4-Independent, Non-CD4-Tropic Simian Immunodeficiency Virus..  90:4966-4980. 2016
  • Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens..  90:4133-4149. 2016
  • A Highly Conserved Residue of the HIV-1 gp120 Inner Domain Is Important for Antibody-Dependent Cellular Cytotoxicity Responses Mediated by Anti-cluster A Antibodies..  90:2127-2134. 2016
  • Enhanced Immune Responses to HIV-1 Envelope Elicited by a Vaccine Regimen Consisting of Priming with Newcastle Disease Virus Expressing HIV gp160 and Boosting with gp120 and SOSIP gp140 Proteins..  90:1682-1686. 2016
  • New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency..  90:76-91. 2016
  • Replication-Competent Influenza B Reporter Viruses as Tools for Screening Antivirals and Antibodies..  89:12226-12231. 2015
  • Breast Milk of HIV-Positive Mothers Has Potent and Species-Specific In Vivo HIV-Inhibitory Activity..  89:10868-10878. 2015
  • Cooperation between the Hepatitis C Virus p7 and NS5B Proteins Enhances Virion Infectivity..  89:11523-11533. 2015
  • Epstein-Barr Viruses (EBVs) Deficient in EBV-Encoded RNAs Have Higher Levels of Latent Membrane Protein 2 RNA Expression in Lymphoblastoid Cell Lines and Efficiently Establish Persistent Infections in Humanized Mice..  89:11711-11714. 2015
  • Phenotypic Correlates of HIV-1 Macrophage Tropism..  89:11294-11311. 2015
  • Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1..  89:9952-9961. 2015
  • Elite Control, Gut CD4 T Cell Sparing, and Enhanced Mucosal T Cell Responses in Macaca nemestrina Infected by a Simian Immunodeficiency Virus Lacking a gp41 Trafficking Motif..  89:10156-10175. 2015
  • Soluble Envelope Glycoprotein Trimers from a CD4-Independent HIV-1 Elicit Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies in Guinea Pigs..  89:10707-10711. 2015
  • A Screen for Extracellular Signal-Regulated Kinase-Primed Glycogen Synthase Kinase 3 Substrates Identifies the p53 Inhibitor iASPP..  89:9232-9241. 2015
  • An Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman Primates..  89:9154-9166. 2015
  • Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1..  89:8840-8854. 2015
  • Epidemiology, Evolution, and Recent Outbreaks of Avian Influenza Virus in China..  89:8671-8676. 2015
  • Rapid Development of gp120-Focused Neutralizing B Cell Responses during Acute Simian Immunodeficiency Virus Infection of African Green Monkeys..  89:9485-9498. 2015
  • Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection..  89:8334-8345. 2015
  • Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research..  89:7478-7493. 2015
  • Comparative Analysis of the Glycosylation Profiles of Membrane-Anchored HIV-1 Envelope Glycoprotein Trimers and Soluble gp140..  89:8245-8257. 2015
  • Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates..  89:8525-8539. 2015
  • Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission..  89:7813-7828. 2015
  • Two-Year Follow-Up of Macaques Developing Intermittent Control of the Human Immunodeficiency Virus Homolog Simian Immunodeficiency Virus SIVmac251 in the Chronic Phase of Infection..  89:7521-7535. 2015
  • Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates..  89:8643-8650. 2015
  • MAVS Coordination of Antiviral Innate Immunity..  89:6974-6977. 2015
  • Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost..  89:6462-6480. 2015
  • Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection..  89:5895-5903. 2015
  • CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus (SIV) vaccine enhances protection against neutralization-resistant mucosal SIV infection..  89:4690-4695. 2015
  • DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers..  89:4158-4169. 2015
  • Unique glycan signatures regulate adeno-associated virus tropism in the developing brain..  89:3976-3987. 2015
  • Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes..  89:2659-2671. 2015
  • Polyreactivity and autoreactivity among HIV-1 antibodies..  89:784-798. 2015
  • RNA populations in immunocompromised patients as reservoirs for novel norovirus variants..  88:14184-14196. 2014
  • Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo..  88:12669-12682. 2014
  • Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies..  88:12623-12643. 2014
  • Induction of viral, 7-methyl-guanosine cap-independent translation and oncolysis by mitogen-activated protein kinase-interacting kinase-mediated effects on the serine/arginine-rich protein kinase..  88:13135-13148. 2014
  • Mitogen-activated protein kinase-interacting kinase regulates mTOR/AKT signaling and controls the serine/arginine-rich protein kinase-responsive type 1 internal ribosome entry site-mediated translation and viral oncolysis..  88:13149-13160. 2014
  • Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection..  88:12895-12906. 2014
  • Viruses and RNA interference: issues and controversies..  88:12934-12936. 2014
  • Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease..  88:11965-11972. 2014
  • CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge..  88:9579-9589. 2014
  • Envelope glycoprotein binding to the integrin α4β7 is not a general property of most HIV-1 strains..  88:10767-10777. 2014
  • Transcriptional and posttranscriptional regulation of cytokine gene expression in HIV-1 antigen-specific CD8+ T cells that mediate virus inhibition..  88:9514-9528. 2014
  • Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial..  88:8242-8255. 2014
  • Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide..  88:9406-9417. 2014
  • HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities..  88:7715-7726. 2014
  • Replication of many human viruses is refractory to inhibition by endogenous cellular microRNAs..  88:8065-8076. 2014
  • CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies..  88:6542-6555. 2014
  • Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity..  88:5165-5170. 2014
  • Identification of novel, highly expressed retroviral microRNAs in cells infected by bovine foamy virus..  88:4679-4686. 2014
  • Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies..  88:2489-2507. 2014
  • Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity..  88:2633-2644. 2014
  • Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques..  88:3329-3339. 2014
  • A vaccine against CCR5 protects a subset of macaques upon intravaginal challenge with simian immunodeficiency virus SIVmac251..  88:2011-2024. 2014
  • Evolutionary conservation of primate lymphocryptovirus microRNA targets..  88:1617-1635. 2014
  • Evolution and diversity in human herpes simplex virus genomes..  88:1209-1227. 2014
  • Resistance to infection, early and persistent suppression of simian immunodeficiency virus SIVmac251 viremia, and significant reduction of tissue viral burden after mucosal vaccination in female rhesus macaques..  88:212-224. 2014
  • Multiple roles for sialylated glycans in determining the cardiopulmonary tropism of adeno-associated virus 4..  87:13206-13213. 2013
  • Robust neutralizing antibodies elicited by HIV-1 JRFL envelope glycoprotein trimers in nonhuman primates..  87:13239-13251. 2013
  • Effects of cellular activation on anti-HIV-1 restriction factor expression profile in primary cells..  87:11924-11929. 2013
  • Epstein-Barr virus induces global changes in cellular mRNA isoform usage that are important for the maintenance of latency..  87:12291-12301. 2013
  • Neutralizing IgG at the portal of infection mediates protection against vaginal simian/human immunodeficiency virus challenge..  87:11604-11616. 2013
  • Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses..  87:10435-10446. 2013
  • Lack of B cell dysfunction is associated with functional, gp120-dominant antibody responses in breast milk of simian immunodeficiency virus-infected African green monkeys..  87:11121-11134. 2013
  • Transient compartmentalization of simian immunodeficiency virus variants in the breast milk of african green monkeys..  87:11292-11299. 2013
  • A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design..  87:10232-10243. 2013
  • Evolutionarily conserved epitopes on human immunodeficiency virus type 1 (HIV-1) and feline immunodeficiency virus reverse transcriptases detected by HIV-1-infected subjects..  87:10004-10015. 2013
  • Heavy chain-only IgG2b llama antibody effects near-pan HIV-1 neutralization by recognizing a CD4-induced epitope that includes elements of coreceptor- and CD4-binding sites..  87:10173-10181. 2013
  • Immune focusing and enhanced neutralization induced by HIV-1 gp140 chemical cross-linking..  87:10163-10172. 2013
  • Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains..  87:10047-10058. 2013
  • In vivo bioluminescent imaging of influenza a virus infection and characterization of novel cross-protective monoclonal antibodies..  87:8272-8281. 2013
  • Quantitative and qualitative differences in the T cell response to HIV in uninfected Ugandans exposed or unexposed to HIV-infected partners..  87:9053-9063. 2013
  • Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design..  87:7218-7233. 2013
  • Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees..  87:7828-7836. 2013
  • Mucosal immunization of lactating female rhesus monkeys with a transmitted/founder HIV-1 envelope induces strong Env-specific IgA antibody responses in breast milk..  87:6986-6999. 2013
  • Mutational inactivation of herpes simplex virus 1 microRNAs identifies viral mRNA targets and reveals phenotypic effects in culture..  87:6589-6603. 2013
  • A cluster of virus-encoded microRNAs accelerates acute systemic Epstein-Barr virus infection but does not significantly enhance virus-induced oncogenesis in vivo..  87:5437-5446. 2013
  • Antibody-DEPENDENT, FcγRI-mediated neutralization of HIV-1 in TZM-bl cells occurs independently of phagocytosis..  87:5287-5290. 2013
  • Dendritic cell immunoreceptor regulates Chikungunya virus pathogenesis in mice..  87:5697-5706. 2013
  • Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes..  87:5372-5383. 2013
  • Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1..  87:4185-4201. 2013
  • Immunogenicity of a vaccine regimen composed of simian immunodeficiency virus DNA, rMVA, and viral particles administered to female rhesus macaques via four different mucosal routes..  87:4738-4750. 2013
  • Biophysical and ultrastructural characterization of adeno-associated virus capsid uncoating and genome release..  87:2994-3002. 2013
  • Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure..  87:3538-3548. 2013
  • Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial..  87:1708-1719. 2013
  • Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion..  87:1554-1568. 2013
  • Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family..  86:11521-11532. 2012
  • Analysis of Epstein-Barr virus-regulated host gene expression changes through primary B-cell outgrowth reveals delayed kinetics of latent membrane protein 1-mediated NF-κB activation..  86:11096-11106. 2012
  • Glycan binding avidity determines the systemic fate of adeno-associated virus type 9..  86:10408-10417. 2012
  • Memory CD4(+) T lymphocytes in the gastrointestinal tract are a major source of cell-associated simian immunodeficiency virus in chronic nonpathogenic infection of African green monkeys..  86:11380-11385. 2012
  • A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies..  86:8319-8323. 2012
  • Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies..  86:8516-8526. 2012
  • Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles..  86:7752-7759. 2012
  • HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages..  86:7496-7507. 2012
  • The development of CD4 binding site antibodies during HIV-1 infection..  86:7588-7595. 2012
  • A novel variant marking HLA-DP expression levels predicts recovery from hepatitis B virus infection..  86:6979-6985. 2012
  • Human galectin 3 binding protein interacts with recombinant adeno-associated virus type 6..  86:6620-6631. 2012
  • Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication..  86:6835-6846. 2012
  • The Epstein-Barr virus (EBV)-induced tumor suppressor microRNA MiR-34a is growth promoting in EBV-infected B cells..  86:6889-6898. 2012
  • Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection..  86:4129-4138. 2012
  • Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge..  86:4644-4657. 2012
  • Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design..  86:4688-4692. 2012
  • Attenuation of neurovirulence, biodistribution, and shedding of a poliovirus:rhinovirus chimera after intrathalamic inoculation in Macaca fascicularis..  86:2750-2759. 2012
  • Control of innate immune signaling and membrane targeting by the Hepatitis C virus NS3/4A protease are governed by the NS3 helix α0..  86:3112-3120. 2012
  • Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages..  86:2715-2728. 2012
  • Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses..  86:2488-2500. 2012
  • High-mannose glycan-dependent epitopes are frequently targeted in broad neutralizing antibody responses during human immunodeficiency virus type 1 infection..  86:2153-2164. 2012
  • Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins..  86:128-142. 2012
  • Targeted entry via somatostatin receptors using a novel modified retrovirus glycoprotein that delivers genes at levels comparable to those of wild-type viral glycoproteins..  86:373-381. 2012
  • Three-dimensional structures of soluble CD4-bound states of trimeric simian immunodeficiency virus envelope glycoproteins determined by using cryo-electron tomography..  85:12114-12123. 2011
  • Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies..  85:11401-11408. 2011
  • Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation..  85:11725-11731. 2011
  • Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection..  85:11196-11207. 2011
  • Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals..  85:11502-11519. 2011
  • Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors..  85:9998-10009. 2011
  • Fitness costs and diversity of the cytotoxic T lymphocyte (CTL) response determine the rate of CTL escape during acute and chronic phases of HIV infection..  85:10518-10528. 2011
  • Primary infection by a human immunodeficiency virus with atypical coreceptor tropism..  85:10669-10681. 2011
  • The members of an Epstein-Barr virus microRNA cluster cooperate to transform B lymphocytes..  85:9801-9810. 2011
  • HIV-specific functional antibody responses in breast milk mirror those in plasma and are primarily mediated by IgG antibodies..  85:9555-9567. 2011
  • High cell-free virus load and robust autologous humoral immune responses in breast milk of simian immunodeficiency virus-infected african green monkeys..  85:9517-9526. 2011
  • Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01..  85:8954-8967. 2011
  • Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins..  85:8514-8527. 2011
  • epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals..  85:9286-9299. 2011
  • Characterization of glycosylation profiles of HIV-1 transmitted/founder envelopes by mass spectrometry..  85:8270-8284. 2011
  • Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual..  85:7719-7729. 2011
  • The genetic bottleneck in vertical transmission of subtype C HIV-1 is not driven by selection of especially neutralization-resistant virus from the maternal viral population..  85:8253-8262. 2011
  • An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum..  85:7029-7036. 2011
  • Antibody-dependent cell-mediated cytotoxicity in simian immunodeficiency virus-infected rhesus monkeys..  85:6906-6912. 2011
  • Evolution of drug-resistant viral populations during interruption of antiretroviral therapy..  85:6403-6415. 2011
  • Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques..  85:6442-6452. 2011
  • Adaptation of an ICAM-1-tropic enterovirus to the mouse respiratory tract..  85:5606-5617. 2011
  • Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen..  85:5764-5772. 2011
  • Differences in HIV-specific T cell responses between HIV-exposed and -unexposed HIV-seronegative individuals..  85:3507-3516. 2011
  • Origin and evolution of HIV-1 in breast milk determined by single-genome amplification and sequencing..  85:2751-2763. 2011
  • Nonneutralizing HIV-1 gp41 envelope cluster II human monoclonal antibodies show polyreactivity for binding to phospholipids and protein autoantigens..  85:1340-1347. 2011
  • Virally induced cellular microRNA miR-155 plays a key role in B-cell immortalization by Epstein-Barr virus..  84:11670-11678. 2010
  • Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys..  84:10406-10412. 2010
  • Viral cell death inhibitor MC159 enhances innate immunity against vaccinia virus infection..  84:10467-10476. 2010
  • Limited contribution of mucosal IgA to Simian immunodeficiency virus (SIV)-specific neutralizing antibody response and virus envelope evolution in breast milk of SIV-infected, lactating rhesus monkeys..  84:8209-8218. 2010
  • HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells..  84:6505-6514. 2010
  • Wide variation in the multiplicity of HIV-1 infection among injection drug users..  84:6241-6247. 2010
  • A human herpesvirus microRNA inhibits p21 expression and attenuates p21-mediated cell cycle arrest..  84:5229-5237. 2010
  • Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination..  84:4998-5006. 2010
  • Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs..  84:3270-3279. 2010
  • Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4..  84:3443-3453. 2010
  • Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies..  84:1439-1452. 2010
  • Herpes simplex virus proteins ICP27 and UL47 associate with polyadenylate-binding protein and control its subcellular distribution..  84:270-279. 2010
  • Identification of viral microRNAs expressed in human sacral ganglia latently infected with herpes simplex virus 2..  84:1189-1192. 2010
  • In-depth analysis of Kaposi's sarcoma-associated herpesvirus microRNA expression provides insights into the mammalian microRNA-processing machinery..  84:695-703. 2010
  • Analysis of human alphaherpesvirus microRNA expression in latently infected human trigeminal ganglia..  83:10677-10683. 2009
  • Derivation and characterization of a simian immunodeficiency virus SIVmac239 variant with tropism for CXCR4..  83:9911-9922. 2009
  • Effect of B-cell depletion on viral replication and clinical outcome of simian immunodeficiency virus infection in a natural host..  83:10347-10357. 2009
  • Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiretroviral therapy..  83:9731-9742. 2009
  • Stable docking of neutralizing human immunodeficiency virus type 1 gp41 membrane-proximal external region monoclonal antibodies 2F5 and 4E10 is dependent on the membrane immersion depth of their epitope regions..  83:10211-10223. 2009
  • Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors..  83:8925-8937. 2009
  • Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys..  83:9584-9590. 2009
  • T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces..  83:8300-8314. 2009
  • Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1..  83:8289-8292. 2009
  • Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41..  83:7397-7410. 2009
  • Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo..  83:6817-6824. 2009
  • Identification of Ongoing HIV-1 Replication in Residual Viremia during Recombinant HIV-1 Poxvirus Immunizations in Patients with Clinically Undetectable Viral Loads on Durable Suppressive HAART. 2009
  • Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses..  83:5505-5513. 2009
  • Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia..  83:4102-4111. 2009
  • High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection..  83:3288-3297. 2009
  • In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth..  83:3617-3625. 2009
  • Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants..  83:3556-3567. 2009
  • Comparisons of CD8+ T cells specific for human immunodeficiency virus, hepatitis C virus, and cytomegalovirus reveal differences in frequency, immunodominance, phenotype, and interleukin-2 responsiveness..  83:2728-2742. 2009
  • Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination..  83:2201-2215. 2009
  • MDM2-dependent inhibition of p53 is required for Epstein-Barr virus B-cell growth transformation and infected-cell survival..  83:2491-2499. 2009
  • Partial protection of Simian immunodeficiency virus (SIV)-infected rhesus monkeys against superinfection with a heterologous SIV isolate..  83:2686-2696. 2009
  • Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carries env isolated from an infant with a recent HIV clade C infection..  83:1422-1432. 2009
  • Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques..  83:791-801. 2009
  • Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism..  82:11889-11901. 2008
  • Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia..  82:12449-12463. 2008
  • Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C..  82:11651-11668. 2008
  • Early B-cell activation after West Nile virus infection requires alpha/beta interferon but not antigen receptor signaling..  82:10964-10974. 2008
  • Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination..  82:7369-7378. 2008
  • Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design..  82:7700-7710. 2008
  • An engineered Saccharomyces cerevisiae strain binds the broadly neutralizing human immunodeficiency virus type 1 antibody 2G12 and elicits mannose-specific gp120-binding antibodies..  82:6447-6457. 2008
  • Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens..  82:6869-6879. 2008
  • Human T-cell leukemia virus type 1 tax attenuates the ATM-mediated cellular DNA damage response..  82:6952-6961. 2008
  • Increased loss of CCR5+ CD45RA- CD4+ T cells in CD8+ lymphocyte-depleted Simian immunodeficiency virus-infected rhesus monkeys..  82:5618-5630. 2008
  • Surface loop dynamics in adeno-associated virus capsid assembly..  82:5178-5189. 2008
  • Induction of Plasma (TRAIL), TNFR-2, Fas Ligand and Plasma Microparticles After HIV-1 Transmission: Implications for HIV-1 Vaccine Design. 2008
  • Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing..  82:3952-3970. 2008
  • Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection..  82:115-125. 2008
  • Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses..  82:638-651. 2008
  • Increased immunogenicity of a DNA-launched Venezuelan equine encephalitis virus-based replicon DNA vaccine..  81:13412-13423. 2007
  • Inhibition of alpharetrovirus replication by a range of human APOBEC3 proteins..  81:13694-13699. 2007
  • Translation by the adenovirus tripartite leader: elements which determine independence from cap-binding protein complex.  64:2669-2677. 1990
  • Correction for Chakrabarti et al., Robust Neutralizing Antibodies Elicited by HIV-1 JRFL Envelope Glycoprotein Trimers in Nonhuman Primates..  89:887. 2015
  • Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost. 2019